The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value
- PMID: 37474663
- DOI: 10.1007/s11547-023-01682-x
The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value
Abstract
Purpose: To investigate the significance of the predominant component of combined hepatocellular-cholangiocarcinoma (cHCC-CC) in terms of MRI manifestation and its potential prognostic value compared to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
Materials and methods: A total of 300 patients with chronic liver disease from two centers were retrospectively enrolled, including 100 surgically proven cases of cHCC-CC, HCC, and ICC each. Univariate and multivariate regression analyses were performed to identify independent predictors for distinguishing HCC-predominant cHCC-CC and ICC-predominant cHCC-CC from HCC and ICC, respectively. Diagnostic models were constructed based on the independent features. Recurrence-free survival (RFS) was estimated and compared between groups.
Results: The predominant component was an independent predictor for RFS in cHCC-CC (hazard ratio = 1.957, P = 0.044). The presence of targetoid appearance (odds ratio(OR) = 10.907, P = 0.001), lack of enhancing capsule (OR = 0.072, P = 0.001) and arterial peritumoral enhancement (OR = 0.091, P = 0.003) were independent predictors suggestive of HCC-predominant cHCC-CC over HCC; their combination yielded an area under the curve of 0.756. No significant differences were observed in RFS between HCC-predominant cHCC-CC and HCC (P = 0.864). Male gender (OR = 4.049, P = 0.015), higher alpha fetoprotein (OR = 16.789, P < 0.001) and normal carbohydrate antigen 19-9 (OR = 0.343, P = 0.036) levels, presence of enhancing capsule (OR = 7.819, P < 0.001) and hemorrhage (OR = 23.526, P = 0.004), and lack of targetoid appearance (OR = 0.129, P = 0.005) and liver surface retraction (OR = 0.190, P = 0.021) were independent predictors suggestive of ICC-predominant cHCC-CC over ICC; their combination yielded an area under the curve value of 0.898. ICC-predominant cHCC-CC exhibited poorer survival with shorter RFS than ICC (P = 0.009).
Conclusion: The predominant histopathological component is closely related to the imaging manifestation of cHCC-CC; and more importantly, it plays a significant prognostic role, which may alter the RFS prognosis of cHCC-CC.
Keywords: Combined hepatocellular-cholangiocarcinoma; Diagnosis; Magnetic resonance imaging; Prognosis.
© 2023. Italian Society of Medical Radiology.
Similar articles
-
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021. Int J Med Sci. 2021. PMID: 33390787 Free PMC article.
-
MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.Cancer Imaging. 2018 Feb 27;18(1):8. doi: 10.1186/s40644-018-0142-z. Cancer Imaging. 2018. PMID: 29486800 Free PMC article.
-
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27. Ann Surg Oncol. 2012. PMID: 22451237
-
Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size.Langenbecks Arch Surg. 2023 Mar 15;408(1):119. doi: 10.1007/s00423-023-02858-9. Langenbecks Arch Surg. 2023. PMID: 36918430 Review.
-
Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.Abdom Radiol (NY). 2023 Jun;48(6):2019-2037. doi: 10.1007/s00261-023-03879-0. Epub 2023 Mar 24. Abdom Radiol (NY). 2023. PMID: 36961531 Review.
Cited by
-
Radiomics Beyond Radiology: Literature Review on Prediction of Future Liver Remnant Volume and Function Before Hepatic Surgery.J Clin Med. 2025 Jul 28;14(15):5326. doi: 10.3390/jcm14155326. J Clin Med. 2025. PMID: 40806948 Free PMC article. Review.
-
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.J Clin Med. 2025 Jan 7;14(2):314. doi: 10.3390/jcm14020314. J Clin Med. 2025. PMID: 39860320 Free PMC article. Review.
-
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.J Cancer Res Clin Oncol. 2024 May 23;150(5):270. doi: 10.1007/s00432-024-05781-8. J Cancer Res Clin Oncol. 2024. PMID: 38780656 Free PMC article. Review.
-
Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound.Diagnostics (Basel). 2025 May 29;15(11):1380. doi: 10.3390/diagnostics15111380. Diagnostics (Basel). 2025. PMID: 40506952 Free PMC article. Review.
-
Current advances and future directions in combined hepatocellular and cholangiocarcinoma.Gastroenterol Rep (Oxf). 2024 Apr 15;12:goae031. doi: 10.1093/gastro/goae031. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 38628397 Free PMC article. Review.
References
-
- Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https://doi.org/10.1038/s41572-020-00240-3 - DOI - PubMed
-
- Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 72:95–103. https://doi.org/10.1016/j.jhep.2019.09.007 - DOI - PubMed
-
- Wang Y, Yang Q, Li S, Luo R, Mao S, Shen J (2019) Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clin Radiol 74:407e401-407e410. https://doi.org/10.1016/j.crad.2019.01.016 - DOI
-
- Beaufrère A, Calderaro J, Paradis V (2021) Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74:1212–1224. https://doi.org/10.1016/j.jhep.2021.01.035 - DOI - PubMed
-
- Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188. https://doi.org/10.1111/his.13975 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical